Effect of Unani Formulation(Qurs e Afsanteen) in Non-Alcoholic Fatty liver disease

Efficacy of Qurs e Afsanteen in Non-Alcoholic grade 1 and 2 Fatty Liver Disease: A randomized Placebo Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/078881

Enrollment

Registered

2025-01-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Qurs e Afsanteen: Qurs(tablet) made of afsanteen, tukhm e karafs, asaroon and maghz e badam binded with water made of size 1gm each ,will be given 5gms twice daily with water for 60days

Eligibility

Inclusion criteria

Inclusion criteria: 1) Non-Alcoholic Fatty liver grade 1(Mild) and grade 2(moderate) based on ultrasonography 2) Patients of both genders 3) Age group of 20 TO 60 years 4) BMI less than 39.9 5) If Alcoholic (Male less than 30gms per day And Female less than 20gms per day)

Exclusion criteria

Exclusion criteria: 1)Pregnancy and lactation 2)Fatty liver of grade 3rd (severe) and above. 3)Patients with serious co morbid condition BP 140/90 mmHg and liver failure and renal failure and Hepatic cirrhosis and Cancer and other endocrine illnesses and other types of fatty liver disease caused by Alcohol viral or autoimmune hepatitis and Wilson’s Disease and Chronic disease like CHS Decomposed lung diseases and Carrier of HIV 4)BMI more than 39.9 5)Patients on hypolipidemic drugs 6)Recurrent drug use 7)Excessive Alcohol intake (Average alcohol intake Male more than 30gms per day and Females more than 20gms per day) 8)History of infection surgery trauma hospitalization in past 30days 9)Chronic degenerative disease of non-hepatic region 10)Non-compliance with the treatment 11) Failure to follow up or refusal to continue the study protocol 12) History of Drug use like (Amiodarone Methotrexate Corticosteroids Estrogen warfare Anti-convulsions drugs Anti-psychotic drugs Chemotherapy drugs and any medication for liver in past 6 months

Design outcomes

Primary

Measure	Time frame
1) Changes in grading of fatty liver (USG) 2)Changes in SGOT and SGPT levels 3)Changes in lipid profileTimepoint: at baseline (0th day), and 60th day	—

Secondary

Measure	Time frame
1)Changes in waist circumference 2) Changes in BMITimepoint: at baseline, 15th day, 30th day, 45th day and on 60th day	—

Countries

India

Contacts

Public ContactMohammed Atiq Raza

National Institute of Unani Medicine

kzarnigar15@gmail.com7483244027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026